Martini J, Huertas C, Turlier V, Saint-Martory C, Delarue A
Endocrinology Department, Rangueil University Hospital, Toulouse, France.
Podology Unit, Purpan University Hospital, Toulouse, France.
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):743-747. doi: 10.1111/jdv.14095. Epub 2017 Jan 23.
Peripheral neuronal impairment compromises foot health in patients with diabetes. Clinically, xerosis is the most common mild complication, but it should not be underestimated. An effective treatment must be able to restore the cutaneous barrier and prevent water loss, to maintain adequate hydration and protection.
This study aimed to assess the efficacy of an emollient cream on foot xerosis in patients with diabetes.
This is a prospective, multicenter, randomized, double-blind contralateral vehicle-controlled study in 57 patients with diabetes. Patients were treated twice daily for 27 ± 2 days with the study emollient containing glycerol 15%, liquid and soft paraffin 10%, glycerol monostearate, stearic acid, polydimethylcyclosiloxane, silicone oil, macrogol 600, trolamine, propyl parahydroxybenzoate and purified water (Dexeryl ; Pierre Fabre Medicament, Boulogne, France) or its vehicle (glycerol monostearate, stearic acid, polydimethylcyclosiloxane, silicone oil, macrogol 600, trolamine, propyl parahydroxybenzoate and purified water). Efficacy was assessed after a 28-day treatment period using a validated score [Xerosis Assessment Scale (XAS) score], instrumental measurements and subjective assessment.
The XAS score decreased to 3.2 ± 2.6 points with the emollient and 4.1 ± 2.3 with the vehicle (P = 0.001). Improvement was observed from day 14 (P = 0.012). Compared with the vehicle, the emollient also significantly improved the overall skin score, hydration index, D-Squame (CuDerm Corporation, Dallas, TX, USA) test, skin roughness and patients' opinions.
Treatment with an emollient is effective for improving foot xerosis in patients with diabetes.
周围神经功能障碍会损害糖尿病患者的足部健康。临床上,皮肤干燥是最常见的轻度并发症,但不应被低估。有效的治疗必须能够恢复皮肤屏障并防止水分流失,以保持足够的水分和保护。
本研究旨在评估一种润肤霜对糖尿病患者足部皮肤干燥的疗效。
这是一项针对57例糖尿病患者的前瞻性、多中心、随机、双盲、对侧赋形剂对照研究。患者每天接受两次治疗,持续27±2天,使用含有15%甘油、10%液体和软石蜡、单硬脂酸甘油酯、硬脂酸、聚二甲基环硅氧烷、硅油、聚乙二醇600、三乙醇胺、对羟基苯甲酸丙酯和纯净水的研究用润肤剂(德赛瑞;皮尔法伯制药公司,法国布洛涅)或其赋形剂(单硬脂酸甘油酯、硬脂酸、聚二甲基环硅氧烷、硅油、聚乙二醇600、三乙醇胺、对羟基苯甲酸丙酯和纯净水)。在28天的治疗期后,使用经过验证的评分[皮肤干燥评估量表(XAS)评分]、仪器测量和主观评估来评估疗效。
使用润肤剂时,XAS评分降至3.2±2.6分,使用赋形剂时为4.1±2.3分(P = 0.001)。从第14天开始观察到改善(P = 0.012)。与赋形剂相比,润肤剂还显著改善了总体皮肤评分、水合指数、D-Squame(美国得克萨斯州达拉斯市CuDerm公司)测试、皮肤粗糙度和患者的评价。
使用润肤剂治疗对改善糖尿病患者的足部皮肤干燥有效。